



DAFTAR PUSTAKA

1. Giancane, G., Consolaro, A. LS. Review Juvenile Idiopathic Arthritis : Diagnosis and Treatment. *Rheumatol Ther.* 2016;3:187–207.
2. Kliegman R. et al. Juvenile Idiopathic Arthritis. In: Nelson Textbook of Pediatrics 20th edition. Philadelphia; 2016. p. 1160.
3. Ringold, S. et al. American College of Rheumatology/ArthritisFoundation GUIDeline for the Treatment of Juvenile Idiopathic Arthritis. *Arthritis Care Res (Hoboken)*. 2019;71.
4. Garinasih, Sumadiono PS. Profil Penderita Juvenile Idiopathic Arthritis di Divisi Imunologi Instalasi Kesehatan Anak RSUP Dr. Sardjito Yogyakarta Januari 2012–2018. 2018;
5. Thatayatikom A. DL. Juvenile Idiopathic Arthritis (JIA). *NCBI, Natl Institutes Heal.* 2020;
6. Guzman, J. et al. The Risk and Nature of flares in Juvenile Idiopathic Arthritis. *Pediatr Rheumatol.* 2014;12.
7. Petty R. et al. Juvenile Idiopathic Arthritis. In: Pediatric Rheumatology. 7th editio. 2015. p. 188–204.
8. Jacobson, J.L., Jennifer T. P. Juvenile Idiopathic Arthritis : A Focus on Pharmacologic Management. *J Pediatr Heal Care.* 2018;32:515–28.
9. Mahmud, S.A, Binstad A. Autoantibodies in The Pathogenesis, Diagnosis and Prognosis of Juvenile Idiopathic Arthritis. *Front Immunol.* 2019;9:3168.
10. Aman J et al. Quantifying cutaneous adverse effect of systemic glucocorticoids in patients with rheumatoid arthritis : a cross sectional study. *Clin Exp Rheumatol.* 2017;35:471–6.
11. Giancane, G., Alongi, A., Aravelli A. Update on the pathogenesis and treatment. *Curr Opin Rheumatol.* 2017;29.
12. Sarah, L. et al. Juvenile Idiopathic Arthritis-associated uveitis. *Pediateer Rheumatol.* 2016;14:273.
13. Daniel J et al. Disease Flare After Discontinuation of Anti Tumor Necrosis Factor Therapy in Children with Polyarticular Forms of Juvenile Idiopathic Arthritis with Clinically in active disease. *Arthritis Rheumatol.* 2018;7.
14. Justine AE et al. Possible Enviromental determinants of Juvenile Idiopathic Arthritis. *Rheumatology.* 2010;49:411–25.
15. Nancy W. JIA Flares Fewer with Longer Inactive Disease. *Medpage Rheumatol.* 2018;
16. Hasnoot, A.J. et al. Erythrocyte Sedimentation Rate as Baseline Predictor for the development of Uveitis in Children with Juvenile Idiopathic Arthritis. 2015;159:372–7.
17. Taketomo, C.K., Hodding, J.H., Kraus DM. Pediatric and Neonatal Dosage Handbook



(24th ed). In 2017.

18. Ezgi DB. Glucocorticoid treatment in Juvenile Idiopathic Arthritis. *Rheumatol Int.* 2019;39:13–27.
19. Finch S. et al. Vitamin D and Juvenile Idiopathic Arthritis. *Pediatr Rheumatol.* 2018;16:34.
20. Aljebab, F. et al. Systematic Review of the toxicity of long course oral corticosteroid in children. *PLoS One.* 2018;12:e0170259.
21. Berthold et al. Outcome in Juvenile Idiopathic Arthritis : a population based study from Sweden. *Arthritis Res.* 2019;21:218.
22. Buck D. The PedsQL as a measure of parent rated quality of life in healthy UK toddlers : Psychometric properties and cross cultural comparisons. *Child Health Care.* 2012;16(4):331–8.
23. Keluarga DK. Pedoman Pelaksanaan Stimulasi, Deteksi dan Intervensi Dini Tumbuh Kembang Anak. In: Kemenkes RI. 2016.
24. Thomas, G.D., Campion EW. Mycrocitic Anemia. *N Engl J Med.* 2014;371:1324–31.
25. Sundberg F, Barnard K, Cato A, Beaufort C De, Rami-merhar B. Managing diabetes in preschool children. 2017;1–19.
26. Frakenburg, W.K., Dodds JB. Manual Tes Denver II. second edition. In: Pediatri Sosial/Tumbuh Kembang Anak Bag Ilmu Kesehatan Anak FK UGMRSUP Dr Sardjito. 2018.